Mylan launches generic ADHD drug

Drug maker gets marketing exclusivity to compete against Novartis' branded product

PITTSBURGH — Generic drug maker Mylan has launched its version of a drug for treating attention deficit hyperactivity disorder, the company said Monday.

Mylan announced the launch of dexmethylphenidate hydrochloride extended-release capsules in the 30-mg strength, a generic version of Novartis' Focalin XR. As the first company to win approval for a generic version of the drug, Mylan has 180 days in which to compete exclusively against Novartis' product.

Focalin XR is used to treat ADHD in patients aged 6 and older and had sales of about $67.34 million during the 12-month period that ended in September, according to IMS Health.


Login or Register to post a comment.